StreetInsider.com News Articles

Form 8-K Co-Diagnostics, Inc. For: Mar 09

Tue, 10 Mar 2026 09:26:00 -0400

si-local-file:///var/storage/secattach/20260310/26136889.html

Form 8-K Co-Diagnostics, Inc. For: Mar 09

Tue, 10 Mar 2026 09:26:00 -0400

si-local-file:///var/storage/secattach/20260310/26136889.html

Co-Diagnostics regains NASDAQ compliance, shares to resume trading

Tue, 10 Mar 2026 09:03:10 -0400

Co-Diagnostics Inc. (NASDAQ: CODX) received formal notice from The Nasdaq Stock Market LLC on March 9, 2026, confirming the company has regained compliance with all applicable criteria for continued listing on The Nasdaq Capital Market, according to a company statement.

The molecular diagnostics company met the $1.00 bid price rule and other listing requirements, resulting in the closure of a previously disclosed listing matter. Co-Diagnostics shares will resume trading on Nasdaq effective March 11, 2026.

The Salt Lake City-based company develops molecular diagnostic tests using a proprietary platform for detecting and analyzing nucleic acid molecules. Co-Diagnostics is working on clinical performance studies

Co-Diagnostics regains NASDAQ compliance, shares to resume trading

Tue, 10 Mar 2026 09:03:10 -0400

Co-Diagnostics Regains Compliance with Nasdaq Listing Requirements

Tue, 10 Mar 2026 09:00:00 -0400

SALT LAKE CITY, March 10, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that on March 9, 2026, the Company received formal notice from The Nasdaq Stock Market LLC ("Nasdaq") confirming that the Company has regained compliance with all applicable criteria for continued listing on The Nasdaq Capital Market, including the $1.00 bid price rule. As a result, the previously disclosed listing matter has been closed and

Co-Diagnostics Regains Compliance with Nasdaq Listing Requirements

Tue, 10 Mar 2026 09:00:00 -0400

Co-Diagnostics Regains Compliance with Nasdaq Listing Requirements

Tue, 10 Mar 2026 09:00:00 -0400

Co-Diagnostics Regains Compliance with Nasdaq Listing Requirements

Tue, 10 Mar 2026 09:00:00 -0400

Co-Diagnostics Regains Compliance with Nasdaq Listing Requirements

Tue, 10 Mar 2026 09:00:00 -0400

Co-Diagnostics Regains Compliance with Nasdaq Listing Requirements

Tue, 10 Mar 2026 09:00:00 -0400

Form SCHEDULE 13G/A Co-Diagnostics, Inc. Filed by: Ayrton Capital LLC

Wed, 11 Feb 2026 10:02:00 -0400

si-local-file:///var/storage/secattach/20260211/25981008.html

Form SCHEDULE 13G/A Co-Diagnostics, Inc. Filed by: Ayrton Capital LLC

Wed, 11 Feb 2026 10:02:00 -0400

si-local-file:///var/storage/secattach/20260211/25981008.html

Co-Diagnostics to Showcase PCR Platform at World Health Expo Labs Dubai